Cullen Jumper, MD
Urology · Exeter, NHNPI 1861612244
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,100 of the $3,737 with a category attached, or 83.0%. Boston Scientific accounts for 90.3% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $3,554, more than ten times the $170 reported in 2019.
Across 14 payments — averaging $266.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Johnson & Johnson$191
- Comsort, Inc$100
- Pfizer$70
What the payments were for
- Consulting fees$3,10083%
- Travel & lodging$3279%
- Food & beverage$622%
- Education$2487%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $3,376 |
| Johnson & Johnson | 3 | $191 |
| Comsort, Inc | 1 | $100 |
| Pfizer | 5 | $70 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,737 in reported general payments places this provider in the 80th percentile of 61 urology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $23,965 |
| GemtesaVibegron | 16 | $19,662 |
| Tamsulosin Hcl | 582 | $7,166 |
| Silodosin | 52 | $4,376 |
| Finasteride | 192 | $2,487 |
| Potassium Citrate ErPotassium Citrate | 28 | $2,181 |
| Methenamine Hippurate | 11 | $1,441 |
| Cefpodoxime Proxetil | 60 | $434 |
| Testosterone Cypionate | 33 | $368 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $354 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 32 | $259 |
| Doxazosin Mesylate | 15 | $219 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $203 |
| Oxybutynin Chloride | 16 | $119 |
| Ciprofloxacin Hcl | 20 | $114 |
Paid to pharmacies, not to this prescriber.
Other urology in Exeter
- E William JohnsonExeter$27K
- Frank RichterExeter$115
- Martin GrossKeene$172K
- Ramiro Madden-FuentesConcord$82K
- Jason AkermanManchester$53K
- Lori LernerLebanon$49K
- John MunozManchester$15K
- Arnold WillisKeene$15K
- Samuel SnipesManchester$6K
- Matthew JohnsonNashua$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.